Loading clinical trials...
Loading clinical trials...
A Phase 2a Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, Pharmacokinetics, and Efficacy of Deupirfenidone (LYT-100) in Patients With Breast Cancer-Related Upper Limb Secondary Lymphoedema
Conditions
Interventions
LYT-100 BCRL
Placebo BCRL
Locations
8
United States
City of Hope National Medical Center
Duarte, California, United States
MACRO Trials
Los Angeles, California, United States
Accel Research Network
Maitland, Florida, United States
Accel Research Network
Atlanta, Georgia, United States
University of the Sunshine Coast
Sippy Downs, Queensland, Australia
Ballarat Health Services
Ballarat, Victoria, Australia
Start Date
March 1, 2020
Primary Completion Date
September 9, 2022
Completion Date
September 9, 2022
Last Updated
April 23, 2024
NCT07073586
NCT07355959
NCT05169086
NCT02476357
NCT00215280
Lead Sponsor
PureTech
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions